BSG
DFTX

Black Swift Group’s Definium Therapeutics DFTX Stock Holding History

Black Swift Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,713
Closed -$62.7K – 129
2025
Q1 		$62.7K Buy
+10,713
New +$76.7K 0.01% 115

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Black Swift Group's DFTX Position: Q2 2025 in Review

Black Swift Group sold out of Definium Therapeutics (DFTX) in Q2 2025, closing a stake of 10,713 shares — an estimated $62.7K sold.

Black Swift Group first reported a position in DFTX in Q1 2025 and held it in 1 quarter. The position peaked at $62.7K in Q1 2025. 181 funds tracked by Wall St. Rank hold DFTX as of Q2 2025.

  • Black Swift Group reported no remaining Definium Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Black Swift Group sold 10,713 Definium Therapeutics shares in Q2 2025, an estimated $62.7K.
  • Black Swift Group first reported a position in Definium Therapeutics in Q1 2025 and held it in 1 quarter.
  • Black Swift Group's Definium Therapeutics position peaked at $62.7K in Q1 2025.
  • 181 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2025.

Based on Black Swift Group's 13F filing for Q2 2025, filed 6 Aug 2025.